Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysis
Objectives This study aimed to investigate real‐world data of ixazomib plus lenalidomide and dexamethasone (IRd) therapy for patients with relapsed and refractory multiple myeloma (RRMM). Methods We retrospectively analyzed 122 patients treated with IRd at 16 centers from May 2017 to January 2019 by...
Gespeichert in:
| Veröffentlicht in: | European journal of haematology 2021-04, Vol.106 (4), p.555-562 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 562 |
|---|---|
| container_issue | 4 |
| container_start_page | 555 |
| container_title | European journal of haematology |
| container_volume | 106 |
| creator | Takakuwa, Teruhito Yamamura, Ryosuke Ohta, Kensuke Kaneko, Hitomi Imada, Kazunori Nakaya, Aya Fuchida, Shin‐ichi Shibayama, Hirohiko Matsuda, Mitsuhiro Shimazu, Yutaka Adachi, Yoko Kosugi, Satoru Uchiyama, Hitoji Tanaka, Hirokazu Hanamoto, Hitoshi Shimura, Yuji Kanda, Junya Onda, Yoshiyuki Uoshima, Nobuhiko Yagi, Hideo Yoshihara, Satoshi Hino, Masayuki Shimazaki, Chihiro Takaori‐Kondo, Akifumi Kuroda, Junya Matsumura, Itaru Kanakura, Yuzuru Nomura, Shosaku |
| description | Objectives
This study aimed to investigate real‐world data of ixazomib plus lenalidomide and dexamethasone (IRd) therapy for patients with relapsed and refractory multiple myeloma (RRMM).
Methods
We retrospectively analyzed 122 patients treated with IRd at 16 centers from May 2017 to January 2019 by using the Kansai Myeloma Forum database.
Result
At the start of IRd, the median age was 72 years, 66.7% of patients had IgG type, and the median number of prior therapies was 4, comprising bortezomib (85.4%) and lenalidomide (89.3%)‐based regimens. Disease progression and adverse events accounted for treatment discontinuation in 46 and 32 patients, respectively. The median overall survival (OS) was not reached, and the median progression‐free survival (PFS) was 11.9 months. Sensitivity to bortezomib did not affect the PFS, whereas lenalidomide‐refractory patients had significantly lower PFS than lenalidomide‐sensitive patients, who were comparable to TOURMALINE‐MM1 study. The patients with IgG type had significantly better PFS and OS than those with non‐IgG type.
Conclusion
This study presents the largest real‐world data of patients treated with IRd in Asia. However, in real clinical practice, the patient background is different from the TOURMALINE‐MM1 study, and IRd showed poor efficacy, especially in the non‐IgG type and lenalidomide‐refractory patients with RRMM. |
| doi_str_mv | 10.1111/ejh.13586 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2480274420</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2480274420</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4196-a4b76046fc58f5cd12d29c1e5a0087a03b26313b89ebb8b24379a0575b060b6e3</originalsourceid><addsrcrecordid>eNp1kcFO3DAURS3UCqbAoj9QReoGFmGeHceOu0MISiskNu06sp0X4ZE9ntoJMP36moZ2Ualv4yfr6MjXl5D3FC5omTVuHi5o03bigKyoAKhBgHpDVqCA1ZxzekTe5bwBAKaoPCRHTcOl4MBXZHM_TzYGzFUcK_esf8bgzNrjVns3lH3A9YDPOuD0oHPcYjXGVIXZT27nsQp79DHoT9XlcmdxO2GqEk4p5h3ayT1ipYtrn10-IW9H7TOevp7H5PvN9ber2_ru_vOXq8u72nKqRK25kQK4GG3bja0dKBuYshRbDdBJDY1hoqGN6RQa0xnGG6k0tLI1JbUR2ByTs8W7S_HHjHnqg8sWvddbjHPuGe-ASc4ZFPTjP-gmzqm894VSiiopFS_U-ULZkionHPtdckGnfU-hfymgLwX0vwso7IdX42wCDn_JPz9egPUCPDmP-_-b-uuvt4vyF7TdkDU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2499197794</pqid></control><display><type>article</type><title>Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysis</title><source>Wiley Journals</source><creator>Takakuwa, Teruhito ; Yamamura, Ryosuke ; Ohta, Kensuke ; Kaneko, Hitomi ; Imada, Kazunori ; Nakaya, Aya ; Fuchida, Shin‐ichi ; Shibayama, Hirohiko ; Matsuda, Mitsuhiro ; Shimazu, Yutaka ; Adachi, Yoko ; Kosugi, Satoru ; Uchiyama, Hitoji ; Tanaka, Hirokazu ; Hanamoto, Hitoshi ; Shimura, Yuji ; Kanda, Junya ; Onda, Yoshiyuki ; Uoshima, Nobuhiko ; Yagi, Hideo ; Yoshihara, Satoshi ; Hino, Masayuki ; Shimazaki, Chihiro ; Takaori‐Kondo, Akifumi ; Kuroda, Junya ; Matsumura, Itaru ; Kanakura, Yuzuru ; Nomura, Shosaku</creator><creatorcontrib>Takakuwa, Teruhito ; Yamamura, Ryosuke ; Ohta, Kensuke ; Kaneko, Hitomi ; Imada, Kazunori ; Nakaya, Aya ; Fuchida, Shin‐ichi ; Shibayama, Hirohiko ; Matsuda, Mitsuhiro ; Shimazu, Yutaka ; Adachi, Yoko ; Kosugi, Satoru ; Uchiyama, Hitoji ; Tanaka, Hirokazu ; Hanamoto, Hitoshi ; Shimura, Yuji ; Kanda, Junya ; Onda, Yoshiyuki ; Uoshima, Nobuhiko ; Yagi, Hideo ; Yoshihara, Satoshi ; Hino, Masayuki ; Shimazaki, Chihiro ; Takaori‐Kondo, Akifumi ; Kuroda, Junya ; Matsumura, Itaru ; Kanakura, Yuzuru ; Nomura, Shosaku</creatorcontrib><description>Objectives
This study aimed to investigate real‐world data of ixazomib plus lenalidomide and dexamethasone (IRd) therapy for patients with relapsed and refractory multiple myeloma (RRMM).
Methods
We retrospectively analyzed 122 patients treated with IRd at 16 centers from May 2017 to January 2019 by using the Kansai Myeloma Forum database.
Result
At the start of IRd, the median age was 72 years, 66.7% of patients had IgG type, and the median number of prior therapies was 4, comprising bortezomib (85.4%) and lenalidomide (89.3%)‐based regimens. Disease progression and adverse events accounted for treatment discontinuation in 46 and 32 patients, respectively. The median overall survival (OS) was not reached, and the median progression‐free survival (PFS) was 11.9 months. Sensitivity to bortezomib did not affect the PFS, whereas lenalidomide‐refractory patients had significantly lower PFS than lenalidomide‐sensitive patients, who were comparable to TOURMALINE‐MM1 study. The patients with IgG type had significantly better PFS and OS than those with non‐IgG type.
Conclusion
This study presents the largest real‐world data of patients treated with IRd in Asia. However, in real clinical practice, the patient background is different from the TOURMALINE‐MM1 study, and IRd showed poor efficacy, especially in the non‐IgG type and lenalidomide‐refractory patients with RRMM.</description><identifier>ISSN: 0902-4441</identifier><identifier>EISSN: 1600-0609</identifier><identifier>DOI: 10.1111/ejh.13586</identifier><identifier>PMID: 33476404</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Adverse events ; Bortezomib ; Dexamethasone ; Immunoglobulin G ; Immunotherapy ; ixazomib ; lenalidomide ; Multiple myeloma ; Patients ; real‐world ; Survival ; Targeted cancer therapy</subject><ispartof>European journal of haematology, 2021-04, Vol.106 (4), p.555-562</ispartof><rights>2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd</rights><rights>2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</rights><rights>Copyright © 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4196-a4b76046fc58f5cd12d29c1e5a0087a03b26313b89ebb8b24379a0575b060b6e3</citedby><cites>FETCH-LOGICAL-c4196-a4b76046fc58f5cd12d29c1e5a0087a03b26313b89ebb8b24379a0575b060b6e3</cites><orcidid>0000-0002-0945-0513 ; 0000-0001-5259-0450 ; 0000-0001-8365-3987</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fejh.13586$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fejh.13586$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33476404$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Takakuwa, Teruhito</creatorcontrib><creatorcontrib>Yamamura, Ryosuke</creatorcontrib><creatorcontrib>Ohta, Kensuke</creatorcontrib><creatorcontrib>Kaneko, Hitomi</creatorcontrib><creatorcontrib>Imada, Kazunori</creatorcontrib><creatorcontrib>Nakaya, Aya</creatorcontrib><creatorcontrib>Fuchida, Shin‐ichi</creatorcontrib><creatorcontrib>Shibayama, Hirohiko</creatorcontrib><creatorcontrib>Matsuda, Mitsuhiro</creatorcontrib><creatorcontrib>Shimazu, Yutaka</creatorcontrib><creatorcontrib>Adachi, Yoko</creatorcontrib><creatorcontrib>Kosugi, Satoru</creatorcontrib><creatorcontrib>Uchiyama, Hitoji</creatorcontrib><creatorcontrib>Tanaka, Hirokazu</creatorcontrib><creatorcontrib>Hanamoto, Hitoshi</creatorcontrib><creatorcontrib>Shimura, Yuji</creatorcontrib><creatorcontrib>Kanda, Junya</creatorcontrib><creatorcontrib>Onda, Yoshiyuki</creatorcontrib><creatorcontrib>Uoshima, Nobuhiko</creatorcontrib><creatorcontrib>Yagi, Hideo</creatorcontrib><creatorcontrib>Yoshihara, Satoshi</creatorcontrib><creatorcontrib>Hino, Masayuki</creatorcontrib><creatorcontrib>Shimazaki, Chihiro</creatorcontrib><creatorcontrib>Takaori‐Kondo, Akifumi</creatorcontrib><creatorcontrib>Kuroda, Junya</creatorcontrib><creatorcontrib>Matsumura, Itaru</creatorcontrib><creatorcontrib>Kanakura, Yuzuru</creatorcontrib><creatorcontrib>Nomura, Shosaku</creatorcontrib><title>Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysis</title><title>European journal of haematology</title><addtitle>Eur J Haematol</addtitle><description>Objectives
This study aimed to investigate real‐world data of ixazomib plus lenalidomide and dexamethasone (IRd) therapy for patients with relapsed and refractory multiple myeloma (RRMM).
Methods
We retrospectively analyzed 122 patients treated with IRd at 16 centers from May 2017 to January 2019 by using the Kansai Myeloma Forum database.
Result
At the start of IRd, the median age was 72 years, 66.7% of patients had IgG type, and the median number of prior therapies was 4, comprising bortezomib (85.4%) and lenalidomide (89.3%)‐based regimens. Disease progression and adverse events accounted for treatment discontinuation in 46 and 32 patients, respectively. The median overall survival (OS) was not reached, and the median progression‐free survival (PFS) was 11.9 months. Sensitivity to bortezomib did not affect the PFS, whereas lenalidomide‐refractory patients had significantly lower PFS than lenalidomide‐sensitive patients, who were comparable to TOURMALINE‐MM1 study. The patients with IgG type had significantly better PFS and OS than those with non‐IgG type.
Conclusion
This study presents the largest real‐world data of patients treated with IRd in Asia. However, in real clinical practice, the patient background is different from the TOURMALINE‐MM1 study, and IRd showed poor efficacy, especially in the non‐IgG type and lenalidomide‐refractory patients with RRMM.</description><subject>Adverse events</subject><subject>Bortezomib</subject><subject>Dexamethasone</subject><subject>Immunoglobulin G</subject><subject>Immunotherapy</subject><subject>ixazomib</subject><subject>lenalidomide</subject><subject>Multiple myeloma</subject><subject>Patients</subject><subject>real‐world</subject><subject>Survival</subject><subject>Targeted cancer therapy</subject><issn>0902-4441</issn><issn>1600-0609</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp1kcFO3DAURS3UCqbAoj9QReoGFmGeHceOu0MISiskNu06sp0X4ZE9ntoJMP36moZ2Ualv4yfr6MjXl5D3FC5omTVuHi5o03bigKyoAKhBgHpDVqCA1ZxzekTe5bwBAKaoPCRHTcOl4MBXZHM_TzYGzFUcK_esf8bgzNrjVns3lH3A9YDPOuD0oHPcYjXGVIXZT27nsQp79DHoT9XlcmdxO2GqEk4p5h3ayT1ipYtrn10-IW9H7TOevp7H5PvN9ber2_ru_vOXq8u72nKqRK25kQK4GG3bja0dKBuYshRbDdBJDY1hoqGN6RQa0xnGG6k0tLI1JbUR2ByTs8W7S_HHjHnqg8sWvddbjHPuGe-ASc4ZFPTjP-gmzqm894VSiiopFS_U-ULZkionHPtdckGnfU-hfymgLwX0vwso7IdX42wCDn_JPz9egPUCPDmP-_-b-uuvt4vyF7TdkDU</recordid><startdate>202104</startdate><enddate>202104</enddate><creator>Takakuwa, Teruhito</creator><creator>Yamamura, Ryosuke</creator><creator>Ohta, Kensuke</creator><creator>Kaneko, Hitomi</creator><creator>Imada, Kazunori</creator><creator>Nakaya, Aya</creator><creator>Fuchida, Shin‐ichi</creator><creator>Shibayama, Hirohiko</creator><creator>Matsuda, Mitsuhiro</creator><creator>Shimazu, Yutaka</creator><creator>Adachi, Yoko</creator><creator>Kosugi, Satoru</creator><creator>Uchiyama, Hitoji</creator><creator>Tanaka, Hirokazu</creator><creator>Hanamoto, Hitoshi</creator><creator>Shimura, Yuji</creator><creator>Kanda, Junya</creator><creator>Onda, Yoshiyuki</creator><creator>Uoshima, Nobuhiko</creator><creator>Yagi, Hideo</creator><creator>Yoshihara, Satoshi</creator><creator>Hino, Masayuki</creator><creator>Shimazaki, Chihiro</creator><creator>Takaori‐Kondo, Akifumi</creator><creator>Kuroda, Junya</creator><creator>Matsumura, Itaru</creator><creator>Kanakura, Yuzuru</creator><creator>Nomura, Shosaku</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QG</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0945-0513</orcidid><orcidid>https://orcid.org/0000-0001-5259-0450</orcidid><orcidid>https://orcid.org/0000-0001-8365-3987</orcidid></search><sort><creationdate>202104</creationdate><title>Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysis</title><author>Takakuwa, Teruhito ; Yamamura, Ryosuke ; Ohta, Kensuke ; Kaneko, Hitomi ; Imada, Kazunori ; Nakaya, Aya ; Fuchida, Shin‐ichi ; Shibayama, Hirohiko ; Matsuda, Mitsuhiro ; Shimazu, Yutaka ; Adachi, Yoko ; Kosugi, Satoru ; Uchiyama, Hitoji ; Tanaka, Hirokazu ; Hanamoto, Hitoshi ; Shimura, Yuji ; Kanda, Junya ; Onda, Yoshiyuki ; Uoshima, Nobuhiko ; Yagi, Hideo ; Yoshihara, Satoshi ; Hino, Masayuki ; Shimazaki, Chihiro ; Takaori‐Kondo, Akifumi ; Kuroda, Junya ; Matsumura, Itaru ; Kanakura, Yuzuru ; Nomura, Shosaku</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4196-a4b76046fc58f5cd12d29c1e5a0087a03b26313b89ebb8b24379a0575b060b6e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adverse events</topic><topic>Bortezomib</topic><topic>Dexamethasone</topic><topic>Immunoglobulin G</topic><topic>Immunotherapy</topic><topic>ixazomib</topic><topic>lenalidomide</topic><topic>Multiple myeloma</topic><topic>Patients</topic><topic>real‐world</topic><topic>Survival</topic><topic>Targeted cancer therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Takakuwa, Teruhito</creatorcontrib><creatorcontrib>Yamamura, Ryosuke</creatorcontrib><creatorcontrib>Ohta, Kensuke</creatorcontrib><creatorcontrib>Kaneko, Hitomi</creatorcontrib><creatorcontrib>Imada, Kazunori</creatorcontrib><creatorcontrib>Nakaya, Aya</creatorcontrib><creatorcontrib>Fuchida, Shin‐ichi</creatorcontrib><creatorcontrib>Shibayama, Hirohiko</creatorcontrib><creatorcontrib>Matsuda, Mitsuhiro</creatorcontrib><creatorcontrib>Shimazu, Yutaka</creatorcontrib><creatorcontrib>Adachi, Yoko</creatorcontrib><creatorcontrib>Kosugi, Satoru</creatorcontrib><creatorcontrib>Uchiyama, Hitoji</creatorcontrib><creatorcontrib>Tanaka, Hirokazu</creatorcontrib><creatorcontrib>Hanamoto, Hitoshi</creatorcontrib><creatorcontrib>Shimura, Yuji</creatorcontrib><creatorcontrib>Kanda, Junya</creatorcontrib><creatorcontrib>Onda, Yoshiyuki</creatorcontrib><creatorcontrib>Uoshima, Nobuhiko</creatorcontrib><creatorcontrib>Yagi, Hideo</creatorcontrib><creatorcontrib>Yoshihara, Satoshi</creatorcontrib><creatorcontrib>Hino, Masayuki</creatorcontrib><creatorcontrib>Shimazaki, Chihiro</creatorcontrib><creatorcontrib>Takaori‐Kondo, Akifumi</creatorcontrib><creatorcontrib>Kuroda, Junya</creatorcontrib><creatorcontrib>Matsumura, Itaru</creatorcontrib><creatorcontrib>Kanakura, Yuzuru</creatorcontrib><creatorcontrib>Nomura, Shosaku</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Animal Behavior Abstracts</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Takakuwa, Teruhito</au><au>Yamamura, Ryosuke</au><au>Ohta, Kensuke</au><au>Kaneko, Hitomi</au><au>Imada, Kazunori</au><au>Nakaya, Aya</au><au>Fuchida, Shin‐ichi</au><au>Shibayama, Hirohiko</au><au>Matsuda, Mitsuhiro</au><au>Shimazu, Yutaka</au><au>Adachi, Yoko</au><au>Kosugi, Satoru</au><au>Uchiyama, Hitoji</au><au>Tanaka, Hirokazu</au><au>Hanamoto, Hitoshi</au><au>Shimura, Yuji</au><au>Kanda, Junya</au><au>Onda, Yoshiyuki</au><au>Uoshima, Nobuhiko</au><au>Yagi, Hideo</au><au>Yoshihara, Satoshi</au><au>Hino, Masayuki</au><au>Shimazaki, Chihiro</au><au>Takaori‐Kondo, Akifumi</au><au>Kuroda, Junya</au><au>Matsumura, Itaru</au><au>Kanakura, Yuzuru</au><au>Nomura, Shosaku</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysis</atitle><jtitle>European journal of haematology</jtitle><addtitle>Eur J Haematol</addtitle><date>2021-04</date><risdate>2021</risdate><volume>106</volume><issue>4</issue><spage>555</spage><epage>562</epage><pages>555-562</pages><issn>0902-4441</issn><eissn>1600-0609</eissn><abstract>Objectives
This study aimed to investigate real‐world data of ixazomib plus lenalidomide and dexamethasone (IRd) therapy for patients with relapsed and refractory multiple myeloma (RRMM).
Methods
We retrospectively analyzed 122 patients treated with IRd at 16 centers from May 2017 to January 2019 by using the Kansai Myeloma Forum database.
Result
At the start of IRd, the median age was 72 years, 66.7% of patients had IgG type, and the median number of prior therapies was 4, comprising bortezomib (85.4%) and lenalidomide (89.3%)‐based regimens. Disease progression and adverse events accounted for treatment discontinuation in 46 and 32 patients, respectively. The median overall survival (OS) was not reached, and the median progression‐free survival (PFS) was 11.9 months. Sensitivity to bortezomib did not affect the PFS, whereas lenalidomide‐refractory patients had significantly lower PFS than lenalidomide‐sensitive patients, who were comparable to TOURMALINE‐MM1 study. The patients with IgG type had significantly better PFS and OS than those with non‐IgG type.
Conclusion
This study presents the largest real‐world data of patients treated with IRd in Asia. However, in real clinical practice, the patient background is different from the TOURMALINE‐MM1 study, and IRd showed poor efficacy, especially in the non‐IgG type and lenalidomide‐refractory patients with RRMM.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>33476404</pmid><doi>10.1111/ejh.13586</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-0945-0513</orcidid><orcidid>https://orcid.org/0000-0001-5259-0450</orcidid><orcidid>https://orcid.org/0000-0001-8365-3987</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0902-4441 |
| ispartof | European journal of haematology, 2021-04, Vol.106 (4), p.555-562 |
| issn | 0902-4441 1600-0609 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2480274420 |
| source | Wiley Journals |
| subjects | Adverse events Bortezomib Dexamethasone Immunoglobulin G Immunotherapy ixazomib lenalidomide Multiple myeloma Patients real‐world Survival Targeted cancer therapy |
| title | Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T12%3A55%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Outcomes%20of%20ixazomib/lenalidomide/dexamethasone%20for%20multiple%20myeloma:%20A%20multicenter%20retrospective%20analysis&rft.jtitle=European%20journal%20of%20haematology&rft.au=Takakuwa,%20Teruhito&rft.date=2021-04&rft.volume=106&rft.issue=4&rft.spage=555&rft.epage=562&rft.pages=555-562&rft.issn=0902-4441&rft.eissn=1600-0609&rft_id=info:doi/10.1111/ejh.13586&rft_dat=%3Cproquest_cross%3E2480274420%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2499197794&rft_id=info:pmid/33476404&rfr_iscdi=true |